Discovery and Development Programs
R&D Pipeline
Gubra’s robust R&D pipeline is centered on the discovery and development of peptide-based therapeutics. Fueled by our proprietary StreaMLine platform, we are advancing a growing portfolio across diverse therapeutic areas, including including metabolic, endocrine, and rare disorders. Our approach is rooted in deep peptide expertise and supported by a broad platform of validated and translational in vivo models.
Why Gubra?
- AI, machine learning, and high-throughput screening to rapidly transform peptide hits into optimized, IP-protected development candidates
- Expertise across metabolic, fibrotic, inflammatory, CNS, respiratory, and women’s health
- Deep scientific knowledge combined with translational in vivo models, ultimately building confidence early in clinical development.
Consult with Louise S. Dalbøge
Chief Science Officer
Choose the right, trustworthy discovery partner.
Balanced portfolio of internal & partnered programs
Gubra’s R&D Pipeline
Background
With current weight loss treatments, 20–40% of body weight reduction comes from unwanted loss of lean mass (muscles, bones, internal organs). Gubra’s UCN2 program is developed for high quality weight loss. In preclinical models UCN2 prevented incretin induced lean mass loos while enhancing fat mass reduction.
Compound
Urocortin-2 analogue and a potent and highly selective Corticotropin-releasing hormone receptor 2 (CRHR2) agonist that has been designed for weekly dosing.
Internal
Background
Narcolepsy type 1 is characterized by the loss of hypothalamic neurons producing orexin (hypocretin), a neuropeptide critical for maintaining wakefulness. Orexin receptor agonists activate orexin receptors (OX1R/OX2R), compensating for the deficiency. This mechanism directly targets the underlying pathophysiology, offering a therapeutic potential to improve clinical symptoms such as excessive daytime sleepiness and cataplexy.
Compound
A novel, peptide-based dual orexin receptor agonist designed to restore the underlying orexin deficiency and reestablish normal wakefulness regulation.
Internal
Background
Injectable peptide-based GLP-1 receptor (GLP1R) agonists have shown remarkable therapeutic success in the treatment of type2 diabetes and obesity, as a monotherapy or in combinations.
Compound
Potent and selective GLP-1 receptor agonist from secretin backbone with good formulation properties excellent in vivo efficacy and PK properties.
Internal
Background
Hypoparathyroidism is a rare endocrine disorder in which the body produces insufficient levels of parathyroid hormone (PTH). PTH is crucial for regulating and maintaining a balance of calcium and phosphorus in the body. Low PTH levels lead to hypocalcemia and hyperphosphatemia, which can lead to muscle cramps, tingling sensations, and in severe cases, seizures or cardiac issues.
Compound
A novel, peptide-based PTH receptor agonist designed to restore calcium and phosphate levels in patients suffering from hypoparathyroidism.
Internal
Background
Despite significant advancements with approved anti-obesity medications, a substantial medical need persists. Current therapies, while effective for many, often fall short in delivering sustained, long-term and muscle preserving weight loss.
Compound
Undisclosed
Internal
Background
AbbVie and Gubra announced a license agreement to develop an amylin analog for the treatment of obesity. The agreement enables the incorporation of GUB014295, an amylin analogue discovered and developed by Gubra, into AbbVie's global infrastructure (ABBV-295). Amylin is a naturally occurring hormone secreted by pancreatic beta cells that plays a crucial role in energy balance and glucose homeostasis. As a satiety signal, it activates pathways in the brain to suppress appetite and reduce food intake.
Compound
A long-acting amylin analog.
Partner
Clinical
The Phase 1 clinical trial is a two-part, single center, double-blind (within cohorts), randomized, placebo-controlled, single (Part 1) and multiple (Part 2) ascending subcutaneous dose study of GUB014295. Part 1 has been completed; Part 2 is ongoing. More information on this trial can be found at https://www.clinicaltrials.gov/ (NCT: 06144684).
Background
BI 1820237, which is fully outlicensed to Boehringer Ingelheim, is a long-acting neuropeptide Y receptor type 2 (NPY2R) agonist. In October 2024, Boehringer Ingelheim discontinued its development for obesity. Potential opportunities outside the obesity indication are now being explored by Boehringer Ingelheim.
Compound
Undisclosed
Partner
Background
BI 3034701, fully outlicensed to Boehringer Ingelheim, is a triple agonist peptide.
Compound
A long-acting triple agonist peptide with a potential to become a next-generation and first-in-class obesity treatment.
Partner
Clinical
The Phase 1, first-in-human, randomized, placebo-controlled trial, will assess safety, tolerability, and pharmacokinetics of the drug candidate (BI 3034701). The trial has 2 parts. Part A is open to healthy men between 18 and 55 years of age. Part B is open to people between 18 and 65 years of age with overweight or obesity who are otherwise healthy.
Background
Building on a longstanding partnership, Boehringer Ingelheim and Gubra continue their collaborative efforts to identify and validate novel peptide-based therapies for obesity. Leveraging complementary strengths in Research and Development , the partnership aims to deliver innovative peptide treatments to improve health outcomes for people living with obesity.
Compound
Undisclosed
Partner
Background
Further building on their history of successful partnership, Gubra and Boehringer Ingelheim have entered a collaboration taking a new approach to discover novel peptides to deliver innovative treatments with the aim of improving health outcomes for people living with obesity.
Compound
Undisclosed
Partner
Background
Collaboration with Amylyx Pharmaceuticals to develop a novel long-acting GLP-1 Receptor Antagonist.
Compound
Undisclosed
Partner
Background
Undisclosed
Compound
Undisclosed
Partner
“
Our scientific expertise, combined with AI-driven platforms, is the foundation of our strong pipeline.
Related pages
For further information
Contact us
Gubra
Hørsholm Kongevej 11B
2970 Hørsholm
Denmark
+45 3152 2650